Please login to the form below

Not currently logged in
Email:
Password:

S-A takeover approach rejected

Sanofi-aventis' suspected takeover approach for Genzyme has been rejected, according to two sources

Sanofi-aventis' (S-A) suspected takeover approach for Genzyme has been rejected, according to two sources.

Analysts have speculated that Genzyme, one of the world's leading biotechnology companies, could command at least $22bn, or $80 a share – a 48 per cent profit over Genzyme's closing price the day before S-A made its approach. It is thought that investors will insist on at least $20bn in a sale.

Genzyme could accrue an annual revenue of $6.6bn by 2013 if it resolves manufacturing defects that resulted in the figure dropping to $4.5bn in 2009.

GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) have also been rumoured to be bidding for Genzyme.

S-A and Genzyme have refused to comment on the claims.

27th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics